Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.
| 19.67 | |
| 19.67 | |
| - | |
| 19.67 | |
| 19.67 | |
| 11.405-19.79 | |
| 2 422 M | |
| 38.5686 | |
| 119 M | |
| 434 M | |
| 0.757 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks presents investor...
The United States market has experienced a notable upswing, rising 1.2% over the last week and 35% over the past year, with earnings projected to grow by 15% annually. In this environment, identifying...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
